Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT510 vs Bevacizumab in Healthy Chinese Males
NCT05113511Phase 1Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCT510A in non-small cell lung cancer (NSCLC) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Area Under the Curve from time 0 to infinity at 2016 hours, Area Under the Curve from time 0 to last quantifiable concentration at 2016 hours and 1 more. Started May 2018; status: completed.
02
Drugs
SCT510A
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05113511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113511.